Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination +/- Ribavirin in Subjects With Chronic Genotype 1 HCV Infection

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination +/- Ribavirin in Subjects With Chronic Genotype 1 HCV Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms LONESTAR
  • Sponsors Gilead Sciences

Most Recent Events

  • 03 Dec 2016 Results of post treatment resistance analysis (n=51) using data from this and four other trials (NCT01260350, NCT01701401, NCT01768286, NCT01851330) published in the Journal of Hepatology
  • 21 Jan 2014 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
  • 08 Nov 2013 Results published in the Lancet.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top